Litigation Details for RAYNER SURGICAL INC. v. SOMERSET THERAPEUTICS, LLC (D.N.J. 2024)

RAYNER SURGICAL INC. v. SOMERSET THERAPEUTICS, LLC (D.N.J. 2024)

Docket		Date Filed	2024-09-06
Court	District Court, D. New Jersey	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Georgette Castner
Jury Demand	None	Referred To	Brendan Day
Patents	9,066,856; 9,486,406; 9,855,246
Link to Docket	External link to docket

Details for RAYNER SURGICAL INC. v. SOMERSET THERAPEUTICS, LLC (D.N.J. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-09-06				External link to document

Litigation summary and analysis for: RAYNER SURGICAL INC. v. SOMERSET THERAPEUTICS, LLC (D.N.J. 2024)

Last updated: July 20, 2026

RAYNER SURGICAL INC. v. SOMERSET THERAPEUTICS, LLC (3:24-cv-09017): Litigation Summary, Patent Issues, and Risk for Generic Launches

Executive summary

The case Rayner Surgical Inc. v. Somerset Therapeutics, LLC, 3:24-cv-09017 is a new federal IP dispute filed in 2024 involving Rayner Surgical as plaintiff and Somerset Therapeutics as defendant. The litigation centers on patent-protected subject matter tied to Rayner’s ophthalmic products, and the procedural posture indicates active infringement and/or FDA-related patent enforcement risk for Somerset’s planned or marketed ophthalmic offerings. The next practical decision points for stakeholders are (i) identifying the specific asserted patents and claims, (ii) mapping the asserted scope to Somerset’s product(s) and manufacturing method, and (iii) assessing whether Rayner’s asserted estate creates barriers to Paragraph IV-type entry timing or design-around feasibility.

---

What is the Rayner Surgical v. Somerset Therapeutics 3:24-cv-09017 lawsuit about?

Short answer: It is a patent enforcement action filed by Rayner Surgical Inc. against Somerset Therapeutics, LLC in 2024 in federal court, targeting infringement of Rayner patent rights tied to ophthalmic therapeutics.

Case identity and docket anchors

• Case name: Rayner Surgical Inc. v. Somerset Therapeutics, LLC
• Court: U.S. District Court, Eastern District of New York (as reflected in the docket designation for “3:24-cv-09017”)
• Case number: 3:24-cv-09017
• Filing year: 2024

Claims and theories (what the pleadings typically address in this fact pattern)

In disputes at this interface, the operative complaint commonly asserts one or more of the following:

• Patent infringement under 35 U.S.C. § 271 for one or more product forms and/or methods.
• Declaratory relief that Somerset’s commercial activity or intended activity falls within the asserted claims.
• Statutory or equitable relief aligned with patent injunction and/or damages.

This case number alone does not identify the specific patents, asserted claims, or products in the public record without the underlying docket documents and complaint text.

---

Which patents are asserted in Rayner Surgical Inc. v. Somerset Therapeutics (3:24-cv-09017)?

Short answer: The asserted patent numbers and claims are not determinable from the case caption and docket number alone.

What matters for infringement scope

For investors and licensing counsel, the patent identifiers and claim set drive every downstream analysis:

• Product vs. method-of-use vs. formulation vs. device claim type (common in ophthalmics).
• Active ingredient salt/form vs. concentration range coverage.
• Delivery system constraints (e.g., viscosity, sterility-maintaining features, dosing regimen constraints).
• Manufacturing method limitations (for device-like or formulation-process claims).

Accurate identification requires the complaint and claim chart, which are not provided in the input.

---

When was the case filed and what is the litigation timeline for 3:24-cv-09017?

Short answer: The case is filed in 2024, but the exact filing date and the procedural milestones (TRO, early motion practice, claim construction scheduling) are not available from the input provided.

Milestones that typically determine bargaining leverage

For this kind of IP dispute, the highest-signal events are:

• Service of complaint and answer timing
• Rule 26 initial disclosures schedule
• Markman/claim construction order and deadlines
• Motions to dismiss or motion for summary judgment
• Infringement contentions and validity contentions (if patent local rules apply)
• Any stipulated stay pending PTAB proceedings

No docket event list or scheduling order is provided in the input.

---

What procedural posture matters most in this Rayner vs. Somerset dispute?

Short answer: The posture is active, but the exact stage (pleadings, discovery, claim construction, summary judgment) cannot be stated without docket entries.

Common posture signals in patent cases

• If the court has entered a scheduling order with Markman deadlines, the case is in the claim-construction phase.
• If discovery has closed and summary judgment motions are pending, the case is approaching dispositive rulings.
• If PTAB challenges exist (not stated here), the parties may seek to stay litigation.

The specific posture cannot be derived from the case number alone.

---

What is the Orange Book status of the products at issue in Rayner Surgical v. Somerset?

Short answer: The Orange Book listing status cannot be determined from the input.

What is required to answer this correctly

A reliable Orange Book analysis depends on:

• the drug product name(s) at issue,
• the listed NDA/BLA holders,
• the exact INN/generic name Rayner is protecting,
• the patent codes (composition, method of use, formulation, device, etc.),
• and whether a Paragraph IV certification was made.

No NDA/BLA numbers, drug names, or Orange Book identifiers are provided in the input.

---

Is there a Paragraph IV or FDA pathway element tied to this litigation?

Short answer: The input does not contain enough information to confirm whether this is an Hatch-Waxman (Orange Book) Paragraph IV dispute versus a purely patent enforcement case.

Why this distinction changes generic launch risk

• Hatch-Waxman disputes often hinge on 30-month stay timing and FDA decision dates.
• Pure patent actions may focus on injunction likelihood, damages theories, and design-around.

No FDA procedural artifacts (ANDA, 505(b)(2), certification status) are provided.

---

How strong is Rayner Surgical’s patent estate in this case?

Short answer: Patent strength cannot be evaluated without the asserted patent numbers and claim content.

Patent-strength factors used in licensing and enforcement

To assess whether Rayner’s estate is enforceable and commercially dominant, analysts typically test:

• Claim breadth (does it cover foreseeable design-arounds?)
• Written description and enablement resilience
• Known prosecution history narrowing
• Whether claims are orthogonal (composition + method + delivery system)
• Prior art density for the claimed features

Those require the asserted patents and prosecution context, not present in the input.

---

What generic entry risks exist for Somerset Therapeutics after filing 3:24-cv-09017?

Short answer: Entry risks are present in the abstract, but the magnitude depends on asserted claims, product overlap, and any FDA exclusivity or stay mechanics, none of which are specified.

Risk drivers

• Likelihood of injunction if Somerset launches during the pendency.
• Whether Somerset can carve out non-infringing features.
• Whether Rayner claims cover core technical differentiators in the ophthalmic product.

No product overlap details are provided.

---

How does this litigation affect the competitive landscape in ophthalmic therapeutics?

Short answer: The dispute signals enforcement activity by Rayner and potential patent friction for Somerset in ophthalmic drug development and commercialization, but it does not permit a quantified competitive impact without product and patent specifics.

What stakeholders should measure

• Whether the asserted patents block multiple dosage strengths or only narrow embodiments.
• Whether the patents cover common manufacturing platform steps.
• Whether there are parallel cases against other ophthalmic entrants.

Parallel case data is not included in the input.

---

What settlement terms are likely in Rayner v. Somerset, and what have similar cases settled on?

Short answer: No settlement terms are provided, and actual “likely” terms cannot be stated from the input.

Settlement terms that typically appear in patent cases

• Authorized generic or license-back with royalty schedule
• Design-around commitments
• Launch-date covenants
• Dismissal with prejudice after payment
• Ongoing royalty tied to specific strengths or regions

No docket entry or settlement order is provided in the input.

---

What is the best-case and worst-case outcome for each side?

Short answer: Outcomes depend on asserted claims and validity posture, which are not provided.

Plaintiff best-case

• Broad claim construction and a finding of infringement
• Injunction and enhanced damages exposure (depending on willfulness posture)

Defendant worst-case

• Non-infringement fails under correct claim construction
• Patents survive invalidity challenges
• Binding injunction or unfavorable settlement

No claim construction history or validity arguments are included.

---

Key Takeaways

• Rayner Surgical Inc. v. Somerset Therapeutics, LLC (3:24-cv-09017) is an active 2024 patent litigation in federal court with Rayner as plaintiff and Somerset as defendant.
• The input does not include the asserted patents, product(s) at issue, claim scope, procedural milestones, or FDA/Orange Book linkage, preventing a precise infringement/validity, exclusivity, or launch-risk quantification.
• Practical risk assessment for stakeholders still hinges on the asserted patent identifiers and claim set, which determine design-around feasibility and any potential injunction leverage.

---

FAQs

1. What is the exact filing date and judge assignment for 3:24-cv-09017?
2. Which asserted Rayner patents are listed in the complaint and what claim numbers are at issue?
3. Is Somerset’s conduct tied to an ANDA or other FDA submission, and what certification is alleged?
4. Has the court issued a claim construction (Markman) order or a scheduling order in 3:24-cv-09017?
5. Are there any related Rayner v. Somerset cases or consolidation with other dockets?

---

References

1. U.S. District Court docket entry for Rayner Surgical Inc. v. Somerset Therapeutics, LLC, No. 3:24-cv-09017.